Medicinal drugs can cross-react with gut bacterial proteins, but the identification of these off-target interactions is difficult. Multi-omic approaches enabled the discovery of a bacterial peptidase that is inhibited by diabetic drugs and unexpectedly influences bacterial fitness within complex microbial communities via a non-proteolytic mechanism.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Vázquez-Baeza, Y. et al. Annu. Rev. Pharmacol. Toxicol. 58, 253–270 (2018).
Haiser, H. J. et al. Science 341, 295–298 (2013).
Zimmermann, M. et al. Science 363, eaat9931 (2019).
Maini Rekdal, V. et al. Science 364, eaau6323 (2019).
Keller, L. J. et al. Nat. Chem. Biol. https://doi.org/10.1038/s41589-023-01357-8 (2023).
Wright, A. T. et al. Isr. J. Chem. 63, e202200099 (2023).
Simon, G. M. & Cravatt, B. F. J. Biol. Chem. 285, 11051–1055 (2010).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing interests.
Rights and permissions
About this article
Cite this article
Hatzios, S.K. Moonlighting in the membrane. Nat Chem Biol 19, 1436–1437 (2023). https://doi.org/10.1038/s41589-023-01369-4
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41589-023-01369-4